ELDN
Eledon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.02
+3.07%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 67.9M | 66.3M | 52.0M | 30.3M | 27.1M |
| SG&A Expense | 16.7M | 17.0M | 18.6M | 12.7M | 12.7M |
| General & Admin Expense | 16.7M | 17.0M | 18.6M | 12.7M | 12.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 48.6M |
| Total Operating Expenses | 84.6M | 83.3M | 70.6M | 43.0M | 88.4M |
| Cost and Expenses | 84.6M | 83.3M | 70.6M | 43.0M | 88.4M |
| Operating Income (EBIT) | (84.6M) | (83.3M) | (70.6M) | (43.0M) | (88.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | (13.9M) | 37.7M | 34.8M | (73.5M) | 462.0K |
| Non-Operating Income (excl Interest) | (3.6M) | (37.7M) | (34.8M) | 73.5M | (48.6M) |
| EBT (Pre-Tax Income) | (98.5M) | (45.6M) | (35.8M) | (116.5M) | (88.0M) |
| Income Tax Expense | 35.0K | 35.0K | 431.0K | — | — |
| Bottom Line | |||||
| Net Income | (98.6M) | (45.6M) | (36.2M) | (116.5M) | (88.0M) |
| Earnings from Cont. Ops | (98.6M) | (45.6M) | (36.2M) | (116.5M) | (88.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (99.9M) | (45.6M) | (36.2M) | (116.5M) | (88.0M) |
| Per Share | |||||
| Basic EPS | ($0.99) | ($0.56) | ($0.75) | ($4.73) | ($6.16) |
| Diluted EPS | ($0.99) | ($0.56) | ($0.75) | ($4.73) | ($6.16) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 113.6M | 81.8M | 48.5M | 24.6M | 14.3M |
| Diluted Shares Outstanding | 113.6M | 81.8M | 48.5M | 24.6M | 14.3M |
| Profitability Metrics | |||||
| EBITDA | (80.9M) | (45.3M) | (35.4M) | (116.2M) | (39.4M) |
| D&A | 81.0K | 313.0K | 359.0K | 374.0K | 373.0K |
| EBIT | (81.0M) | (45.6M) | (35.8M) | (116.5M) | (39.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026